Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
AN: Data curation, Investigation, Methodology, Writing original draft
What they found: Oral AOD-9604 reduced body fat by 18 to 22 % vs placebo, comparable to injection administration No changes in total body weight (because lean mass rose slightly) Decrease in plasma triglycerides by 30 % Decrease in resting free fatty acids (paradoxically, mobilization of fat from depots into oxidation) No GI side effects Why it matters: It suggested that AOD-9604 could work orally , a rare property for a peptide
Increased breakdown of fat in the body
Increases Energy Levels Low energy can make it difficult to stick to an exercise routine or stay active throughout the day
One of the websites never replied
community model is usually subcutaneous Evidence level Published duration, but different routes and doses Timeline 16 weeks Where it comes from Community research planning Route studied or discussed Usually discussed as subcutaneous Evidence level Anecdotal Timeline 24 weeks Where it comes from METAOD006 human trial Route studied or discussed Oral tablets Evidence level Published duration
